Translational Study on the Effects of Janus Kinase Inhibitors on Interstitial Lung Disease Complicated with Rheumatoid Arthritis
5 affiliations
- 1Department of Pathogenesis and Translational Medicine, Showa Medical University Graduate School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
- 2Division of Pathogenesis and Translational Medicine, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
- 3Division of Rheumatology, Department of Medicine, Showa Medical University Graduate School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
- 4Department of Microbiology and Immunology, Showa Medical University Graduate School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
- 5Division of Nephrology, Department of Medicine, Showa Medical University Graduate School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
Abstract
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a major cause of morbidity and mortality in patients with rheumatoid arthritis. This study evaluated the 1-year retention rates of Janus kinase (JAK) inhibitors in patients with RA-ILD and investigated their effects in experimental pulmonary fibrosis and human lung fibroblasts. One-year retention rates were assessed in patients with RA-ILD treated with baricitinib (BAR), peficitinib (PEF), filgotinib (FIL), upadacitinib, or tofacitinib. Pulmonary fibrosis was induced by bleomycin (BLM) in C57BL/6J mice, followed by treatment with BAR, PEF, or FIL. Survival, body weight, computed tomography findings, and histopathology were evaluated. Normal human lung fibroblasts (NHLFs) were stimulated with the interleukin (IL)-6/IL-6 receptor and treated with each JAK inhibitor. STAT1, STAT3, and STAT5 phosphorylation and the production of vascular endothelial growth factor (VEGF), transforming growth factor-β1, and fractalkine were assessed. JAK inhibitor 1-year retention rates did not differ significantly between patients with and without RA-ILD. In the BLM model, BAR attenuated pulmonary inflammation, preserved body weight, and improved survival compared with PEF and FIL. In NHLFs, BAR most effectively suppressed IL-6-induced STAT3 phosphorylation and VEGF production. These findings suggest that BAR may exert protective effects in experimental pulmonary fibrosis through suppression of the IL-6/STAT3/VEGF axis.
Related
- Natural Products for Rheumatoid Arthritis Therapy: Research Progress and Translational Perspectives
- RNA therapeutics in rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis: a compartment-aware translational framework
- Single-cell Transcriptomics in Autoimmune Diseases: Mechanistic Insights, Cross-disease Convergence, and Translational Challenges in Rheumatoid Arthritis, Systemic Lupus Erythematosus, Type 1 Diabetes, and Multiple Sclerosis.
- A pathway-guided kernel MLP architecture for interpretable cross-disease transfer from rheumatoid arthritis to hematological malignancies
- Differential Expression of Cytotoxic-Associated Markers in Circulating CD4+CD28− T Cells and NK Cells in Rheumatoid Arthritis
BibTeX
@article{kojima2026translational,
title = {{Translational Study on the Effects of Janus Kinase Inhibitors on Interstitial Lung Disease Complicated with Rheumatoid Arthritis}},
author = {Hiroyuki Kojima and Haruka Nakamura and Kohei Maeda and Kosuke Sakurai and Toshihiro Tanioka and Maina Miyatani and Kuninobu Wakabayashi and Yusuke Miwa and Masayuki Iyoda and Takeo Isozaki},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210243},
url = {https://www.mdpi.com/1422-0067/27/22/10243},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Translational Study on the Effects of Janus Kinase Inhibitors on Interstitial Lung Disease Complicated with Rheumatoid Arthritis
AU - Hiroyuki Kojima
AU - Haruka Nakamura
AU - Kohei Maeda
AU - Kosuke Sakurai
AU - Toshihiro Tanioka
AU - Maina Miyatani
AU - Kuninobu Wakabayashi
AU - Yusuke Miwa
AU - Masayuki Iyoda
AU - Takeo Isozaki
PY - 2026
DA - 2026/11/15
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210243
UR - https://www.mdpi.com/1422-0067/27/22/10243
AB - Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a major cause of morbidity and mortality in patients with rheumatoid arthritis. This study evaluated the 1-year retention rates of Janus kinase (JAK) inhibitors in patients with RA-ILD and investigated their effects in experimental pulmonary fibrosis and human lung fibroblasts. One-year retention rates were assessed in patients with RA-ILD treated with baricitinib (BAR), peficitinib (PEF), filgotinib (FIL), upadacitinib, or tofacitinib. Pulmonary fibrosis was induced by bleomycin (BLM) in C57BL/6J mice, followed by treatment with BAR, PEF, or FIL. Survival, body weight, computed tomography findings, and histopathology were evaluated. Normal human lung fibroblasts (NHLFs) were stimulated with the interleukin (IL)-6/IL-6 receptor and treated with each JAK inhibitor. STAT1, STAT3, and STAT5 phosphorylation and the production of vascular endothelial growth factor (VEGF), transforming growth factor-β1, and fractalkine were assessed. JAK inhibitor 1-year retention rates did not differ significantly between patients with and without RA-ILD. In the BLM model, BAR attenuated pulmonary inflammation, preserved body weight, and improved survival compared with PEF and FIL. In NHLFs, BAR most effectively suppressed IL-6-induced STAT3 phosphorylation and VEGF production. These findings suggest that BAR may exert protective effects in experimental pulmonary fibrosis through suppression of the IL-6/STAT3/VEGF axis.
SN - 1422-0067
ER -